A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke
Recruiting
Phase 2/3 Results N/ATrial Description
This is a prospective, randomized, concurrent controlled, multi-center study. Patients presenting with symptoms of acute ischemic stroke who have evidence of a large vessel (>3mm in diameter) occlusion in the cerebral circulation will be assigned to either the Penumbra System with the Separator 3D or the Penumbra System without the Separator 3D. Each treated patient will be followed and assessed for 3 months after randomization. Up to 164 evaluable patients at up to 50 centers presenting with acute ischemic stroke in vessels accessible to the Penumbra Separator 3D System for revascularization within 8 hours of symptom onset. The hypothesis to be tested is that the safety and effectiveness of the Penumbra System with the Separator 3D for the revascularization of large vessel occlusion is not inferior to the Penumbra System alone.
Conditions
Interventions
- Penumbra System with Separator 3D Device
Intervention Desc: The Separator 3D is an additional Separator with a new tip configuration for the Penumbra System. ARM 1: Kind: Experimental Label: Penumbra System with Separator 3D - Penumbra System alone Device
Intervention Desc: The Penumbra System® is a new generation of neuro-embolectomy devices specifically designed to remove thrombus through aspiration.The treatment paradigm of this System involves the introduction of the Reperfusion Catheter through a guide catheter into the intracranial vasculature, and guided over an appropriate guidewire to the site of primary occlusion. The Reperfusion Catheter is used in parallel with the Separator and an aspiration source (Aspiration Pump) to separate the thrombus and aspirate it from the occluded vessel. ARM 1: Kind: Experimental Label: Penumbra System alone
Trial Design
- Allocation: Randomized
- Masking: Single Blind (Subject)
- Purpose: Treatment
- Endpoint: Safety/Efficacy Study
- Intervention: Parallel Assignment
Outcomes
| Type | Measure | Time Frame | Safety Issue |
|---|---|---|---|
| Primary | Angiographic revascularization of the occluded target vessel at immediate post-procedure as defined by a TIMI/TICI score of 2 or 3 | At immediate post-procedure | No |
| Primary | Incidence of device-related and procedure-related serious adverse event | During the procedure | Yes |
| Secondary | Good clinical outcome at 30 days post-procedure as defined by a 10 points or more improvement in the NIHSS at Discharge, a NIHSS score of 0-1at Discharge; or a 30-day mRS score of 0-2 | 30 days post-procedure | No |
| Secondary | The proportion of patients with a modified Rankin Scale (mRS) of ≤ 2 at 90 days post treatment | at 90 days post-procedure | No |
| Secondary | All cause mortality | At 90 days post-procedure | Yes |
| Secondary | Incidence of symptomatic hemorrhage | At 90 days post-procedure | Yes |
Sponsors
- Penumbra Inc. Lead
View Trial Locations
Recruitment
- Enrollment: 230
- Gender: Both
- Minimum Age: 18 Years
- Accepts Healthy Volunteers: No
- 8 locations, 1 country
Principal Investigator
- Don Frei, MD
